Table 4.
Adverse events related to apatinib in the TACE–apatinib group before PSM analysis.
| Adverse events | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | All events |
|---|---|---|---|---|---|---|
| Hand-foot skin reactions | 30 (24%) | 59 (47%) | 8 (6%) | 0 (0%) | 0 (0%) | 97 (77%) |
| Hypertension | 40 (32%) | 17 (13%) | 1 (1%) | 0 (0%) | 0 (0%) | 58 (46%) |
| Diarrhea | 23 (19%) | 6 (5%) | 1 (0%) | 0 (0%) | 0 (0%) | 30 (24%) |
| Fatigue | 20 (16%) | 8 (6%) | 0 (0%) | 0 (0%) | 0 (0%) | 28 (22%) |
| Headache | 10 (8%) | 5 (4%) | 0 (0%) | 0 (0%) | 0 (0%) | 15 (12%) |
| Oral ulcer | 4 (3%) | 5 (4%) | 0 (0%) | 0 (0%) | 0 (0%) | 9 (7%) |
| Voice change | 6 (5%) | 5 (4%) | 0 (0%) | 0 (0%) | 0 (0%) | 11 (9%) |
| Proteinuria | 9 (7%) | 20 (16%) | 1 (1%) | 0 (0%) | 0 (0%) | 30 (24%) |
| Gastrointestinal hemorrhage | 1 (1%) | 1 (1%) | 2 (2%) | 0 (0%) | 0 (0%) | 4 (4%) |
| New hypothyroidism | 0 (0%) | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) | 1 (1%) |
Data are numbers of events. Data in parentheses are percentages.
TACE, transarterial chemoembolization; PSM, propensity score matching.